Contineum Therapeutics (CTNM) Non-Current Assets (2023 - 2026)

Contineum Therapeutics' Non-Current Assets history runs 4 years deep, the most recent figure standing at $7.8 million for Q2 2026.

• In Q2 2026, Non-Current Assets rose 28.73% year-over-year to $7.8 million; the TTM figure through Jun 2026 stood at $30.8 million (up 57.8% YoY), while the FY2025 annual figure was $8.7 million, up 35.08% from the prior year.
• Non-Current Assets for Q2 2026 stood at $7.8 million, down from $8.4 million in the prior quarter.
• The five-year high for Non-Current Assets was $8.7 million in Q4 2025, with the low at $891000.0 in Q3 2024.
• The 4-year median for Non-Current Assets is $6.0 million (2025), against an average of $5.3 million.
• The sharpest annual moves came in 2025 and 2026: Non-Current Assets jumped 564.42% in 2025, then advanced 28.73% in 2026.
• Contineum Therapeutics' Non-Current Assets stood at $2.7 million in 2023, then soared by 141.01% to $6.5 million in 2024, then jumped by 35.08% to $8.7 million in 2025, then slipped by 10.75% to $7.8 million in 2026.
• Business Quant data shows CTNM's Non-Current Assets at $7.8 million in Q2 2026, $8.4 million in Q1 2026, and $8.7 million in Q4 2025.